<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Hypertens</journal-id><journal-id journal-id-type="iso-abbrev">J. Hypertens</journal-id><journal-id journal-id-type="publisher-id">JHYPE</journal-id><journal-title-group><journal-title>Journal of Hypertension</journal-title></journal-title-group><issn pub-type="ppub">0263-6352</issn><issn pub-type="epub">1473-5598</issn><publisher><publisher-name>Lippincott Williams &#x00026; Wilkins</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">24906174</article-id><article-id pub-id-type="pmc">4166043</article-id><article-id pub-id-type="doi">10.1097/HJH.0000000000000239</article-id><article-categories><subj-group subj-group-type="heading"><subject>ORIGINAL PAPERS: Therapeutic aspects</subject></subj-group></article-categories><title-group><article-title>Effects on office and home blood pressure of the lercanidipine-enalapril combination in patients with Stage 2 hypertension: a European randomized, controlled clinical trial</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Mancia</surname><given-names>Giuseppe</given-names></name><xref ref-type="aff" rid="aff1"><sup>a</sup></xref></contrib><contrib contrib-type="author"><name><surname>Coca</surname><given-names>Antonio</given-names></name><xref ref-type="aff" rid="aff2"><sup>b</sup></xref></contrib><contrib contrib-type="author"><name><surname>Chazova</surname><given-names>Irina</given-names></name><xref ref-type="aff" rid="aff3"><sup>c</sup></xref></contrib><contrib contrib-type="author"><name><surname>Girerd</surname><given-names>Xavier</given-names></name><xref ref-type="aff" rid="aff4"><sup>d</sup></xref></contrib><contrib contrib-type="author"><name><surname>Haller</surname><given-names>Hermann</given-names></name><xref ref-type="aff" rid="aff5"><sup>e</sup></xref></contrib><contrib contrib-type="author"><name><surname>Pauletto</surname><given-names>Paolo</given-names></name><xref ref-type="aff" rid="aff6"><sup>f</sup></xref></contrib><contrib contrib-type="author"><name><surname>Pupek-Musialik</surname><given-names>Danuta</given-names></name><xref ref-type="aff" rid="aff7"><sup>g</sup></xref></contrib><contrib contrib-type="author"><name><surname>Svyshchenko</surname><given-names>Yevgeniya</given-names></name><xref ref-type="aff" rid="aff8"><sup>h</sup></xref><on-behalf-of>the FELT investigators</on-behalf-of></contrib></contrib-group><aff id="aff1"><label>a</label>IRCSS, Istituto Auxologico Italiano and University Milano-Bicocca, Milan, Italy</aff><aff id="aff2"><label>b</label>Hospital Cl&#x000ed;nic of Barcelona, University of Barcelona, Barcelona, Spain</aff><aff id="aff3"><label>c</label>Institute of Clinical Cardiology, Department of Systemic Hypertension, Moscow, Russia</aff><aff id="aff4"><label>d</label>Cardiovascular Prevention Unit, H&#x000f4;pital de la Piti&#x000e9; Salp&#x000e9;tri&#x000e8;re, Paris, France</aff><aff id="aff5"><label>e</label>Hannover Medical School, Department of Nephrology and Hypertension, Hannover, Germany</aff><aff id="aff6"><label>f</label>Department of Internal Medicine, University Hospital of Treviso &#x00026; University of Padova, Padova, Italy</aff><aff id="aff7"><label>g</label>Department of Biochemistry and Molecular Biology, Karol Marcinkowski University of Medical Sciences, Poznan, Poland</aff><aff id="aff8"><label>h</label>Strazhesko Institute of Cardiology, Kiev, Ukraine</aff><author-notes><corresp>Correspondence to Giuseppe Mancia, P.za dei Daini, 4, 20126 Milan, Italy. Tel: +39 039 233 3357; fax: +39 039 322274; e-mail: <email>Giuseppe.mancia@unimib.it</email></corresp></author-notes><pub-date pub-type="ppub"><month>8</month><year>2014</year></pub-date><pub-date pub-type="epub"><day>03</day><month>7</month><year>2014</year></pub-date><volume>32</volume><issue>8</issue><fpage>1700</fpage><lpage>1707</lpage><history><date date-type="received"><day>11</day><month>2</month><year>2014</year></date><date date-type="rev-recd"><day>7</day><month>4</month><year>2014</year></date><date date-type="accepted"><day>7</day><month>4</month><year>2014</year></date></history><permissions><copyright-statement>&#x000a9; 2014 Wolters Kluwer Health | Lippincott Williams &#x00026; Wilkins</copyright-statement><copyright-year>2014</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-nd/3.0./"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivitives 3.0 License, where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially. <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/3.0.">http://creativecommons.org/licenses/by-nc-nd/3.0.</ext-link></license-p></license></permissions><self-uri xlink:type="simple" xlink:href="jhype-32-1700.pdf"/><abstract><sec><title>Objectives:</title><p>The aim of this study was to evaluate the efficacy and safety of combinations of lercanidipine (L) and enalapril (E) at different doses on office and home blood pressure (BP) in patients with Stage 2 hypertension.</p></sec><sec><title>Study design:</title><p>This was a randomized, double-blind, placebo-controlled, factorial study conducted in 100 centres from seven countries. Patients with office DBP 100&#x02013;109&#x0200a;mmHg and home DBP at least 85&#x0200a;mmHg at the end of a 2-week placebo run-in period were randomized to a 10-week treatment with placebo, L (10 or 20&#x0200a;mg), E (10 or 20&#x0200a;mg) or the four L-E combinations. The efficacy parameters were office DBP at trough (primary), SBP at trough and home SBP and DBP. Office BP was measured at each visit in both the sitting and the standing position, while home BP was measured twice in the morning and twice in the evening for at least 3 days before treatment and at study end. Safety parameters included adverse events, laboratory tests and 12-lead ECG.</p></sec><sec sec-type="results"><title>Results:</title><p>A total of 1039 patients were randomized (48% men, mean age 54 years, mean BMI 30&#x0200a;kg/m<sup>2</sup>, 40% obese patients). Baseline BP was similar in all groups and lower for home than for office values (149/95 and 159/103&#x0200a;mmHg, respectively). A marked placebo effect was observed on office but not on home BP. Combination therapy was superior to placebo at all doses for both office and home BP. The greatest effect was observed in the L20/E20 group, in which the SBP/DBP fall amounted to &#x02212;19.2/&#x02212;15.2 and &#x02212;13.2/&#x02212;7.5&#x0200a;mmHg for sitting office and home BP, respectively. Similar reductions were observed on standing office BP. The L20/E20 combination was associated with less cough, palpitations and leg oedema than monotherapies, with no increased rate of dizziness or hypotension.</p></sec><sec sec-type="conclusion"><title>Conclusion:</title><p>In Stage 2 hypertension, a fixed-dose combination of L and E ensures a control of both office and out-of-office BP, with a favourable tolerability profile.</p></sec></abstract><kwd-group><title>Keywords</title><kwd>combination therapy</kwd><kwd>enalapril</kwd><kwd>essential hypertension (Stage 2)</kwd><kwd>factorial study design</kwd><kwd>home blood pressure</kwd><kwd>lercanidipine</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>OPEN-ACCESS</meta-name><meta-value>TRUE</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro"><title>INTRODUCTION</title><p>All guidelines on hypertension regard monotherapy as unable to effectively reduce blood pressure (BP) in the majority of patients with a BP elevation and recommend use of combinations of two or more drugs in order to increase the rate by which BP is controlled in the hypertensive population [<xref rid="R1" ref-type="bibr">1</xref>&#x02013;<xref rid="R3" ref-type="bibr">3</xref>]. They also favour initiation of antihypertensive treatment with two rather than one drug in order to guarantee a more rapid BP control and earlier protective effect [<xref rid="R4" ref-type="bibr">4</xref>], and combination of two agents into a single tablet, because simplification of treatment has a favourable effect on adherence to the prescribed regimen [<xref rid="R5" ref-type="bibr">5</xref>,<xref rid="R6" ref-type="bibr">6</xref>].</p><p>Several drug combinations are indicated by guidelines as suitable for preferential use [<xref rid="R1" ref-type="bibr">1</xref>]. Among them, the combination of a dihydropiridine calcium antagonist and an angiotensin-converting enzyme (ACE) inhibitor is of particular importance because randomized trials have shown that this combination may lower effectively the elevated BP [<xref rid="R7" ref-type="bibr">7</xref>,<xref rid="R8" ref-type="bibr">8</xref>], exert a superior cardiovascular protective effect than the diuretic/beta-blocker and ACE inhibitor/calcium antagonist combinations [<xref rid="R9" ref-type="bibr">9</xref>,<xref rid="R10" ref-type="bibr">10</xref>] and reduce the incidence of the most common calcium antagonist related side effect, that is ankle oedema [<xref rid="R11" ref-type="bibr">11</xref>].</p><p>A fixed-dose combination between the calcium antagonist lercanidipine (L) and the ACE inhibitor enalapril (E) is of clinical interest, as both enalapril and lercanidipine are among the most used drugs in their class. Furthermore, E has proved to exert clearcut protective effects in both hypertension and heart failure [<xref rid="R12" ref-type="bibr">12</xref>&#x02013;<xref rid="R15" ref-type="bibr">15</xref>], while L has been shown to be a long-acting drug [<xref rid="R16" ref-type="bibr">16</xref>], with a smooth antihypertensive effect, a favourable tolerability profile and a protective influence on organs damaged by hypertension [<xref rid="R17" ref-type="bibr">17</xref>,<xref rid="R18" ref-type="bibr">18</xref>]. Compared with other calcium antagonists, the L-E combination has also been found to be associated with no chronic reflex activation of the sympathetic nervous [<xref rid="R19" ref-type="bibr">19</xref>], thereby avoiding the adverse effects that sympathetic hyperactivity may have on organ structure and function as well as on cardiovascular risk [<xref rid="R20" ref-type="bibr">20</xref>].</p><p>The L-E combination has already been shown to be effective in hypertensive patients unresponsive to monotherapies [<xref rid="R21" ref-type="bibr">21</xref>,<xref rid="R22" ref-type="bibr">22</xref>]. However, the efficacy and safety of the two drugs when administered at their full therapeutic doses (20&#x0200a;mg/day) has not yet been established by comparisons with monotherapy, combinations of the two drugs at lower doses or placebo. Aim of the present study was to provide this information by a large-scale, randomized, placebo-controlled study on moderate hypertensive patients. The antihypertensive effect was assessed not only by office but also by home BP changes because home BP has been found to have an important prognostic value [<xref rid="R23" ref-type="bibr">23</xref>&#x02013;<xref rid="R25" ref-type="bibr">25</xref>] and is more and more frequently used by physicians to check the effect of the prescribed treatment regimen in an environment closer to daily life than the physician's office.</p></sec><sec sec-type="materials and methods"><title>MATERIALS AND METHODS</title><sec><title>Study population</title><p>The study population consisted of male and female hypertensive patients aged 18 to 75 years, who were untreated, intolerant to the prescribed drugs or not well controlled by the existing antihypertensive therapy. Patients were recruited if their trough office BP values (24&#x0200a;&#x000b1;&#x0200a;2&#x0200a;h after dosing) were between 100 and 109&#x0200a;mmHg for DBP and less than 180&#x0200a;mmHg for SBP after 2 weeks of single-blind placebo treatment, and average home DBP was at least 85&#x0200a;mmHg in the week before randomization. This was done to exclude individuals with isolated office hypertension.</p><p>Other key exclusion criteria included secondary or severe hypertension (patients with a DBP &#x02265;110&#x0200a;mmHg or an SBP &#x02265;180&#x0200a;mmHg), history or presence of cardiovascular disease (transient ischemic attacks, stroke, hypertensive encephalopathy, angina pectoris, myocardial infarction, myocardial revascularization procedures, heart failure), haemodynamically significant valve disease, clinically significant ventricular or supraventricular arrhythmias, heart rate greater than 100&#x0200a;beats/min, severe renal or hepatic insufficiency or diabetes on drug treatment. Women who were pregnant, breastfeeding, planning a pregnancy or having a childbearing potential without using an effective method of contraception were also excluded from the study and so were those with a history of intolerance to dihydropiridine calcium antagonists or ACE inhibitors.</p></sec><sec><title>Study design</title><p>This was an international, multicentre, randomized, placebo-controlled, parallel group study conducted on a total of 100 sites in France, Germany, Italy, Poland, Russia, Spain and Ukraine. The study consisted of a 2-week single-blind placebo run-in period, during which all previous antihypertensive medications (if any) were discontinued, followed by a 10-week double-blind active treatment period. The eligible patients were randomly allocated to one of nine treatment groups: placebo, monotherapy with 10 or 20&#x0200a;mg daily of L, monotherapy with 10 or 20&#x0200a;mg daily of E, or L/E combination at the following daily doses: L10/E10, L10/E 20, L20/10&#x0200a;mg and L20/E20. One capsule containing one or two tablets of L 10&#x0200a;mg and one tablet of E10 or 20&#x0200a;mg were used and all drugs were given in the morning, usually around 0800&#x0200a;h. Randomization was accomplished by assigning each patient a unique individual identification number (composed of the study site number and a screening number) via an interactive voice response system. For safety reasons, individuals assigned to be treated with L20, E20, L10/E20, L20/E10 or L20/E20&#x0200a;mg received a lower dose in the first 2 weeks of treatment before being titrated to the final dosage. Furthermore, individuals with a DBP at least 110&#x0200a;mmHg or an SBP at least 180&#x0200a;mmHg taken at office were removed from the study at any time. Clinic visits were scheduled 2 weeks after the initiation of the single-blind placebo period, at the end of the placebo period and at 2, 4, 6 and 10 weeks after randomization to treatment. Adverse events and concomitant medications were checked at each visit. Laboratory tests, a physical examination and an electrocardiography were performed at screening, before randomization to treatment, at study end or at the time of an early study interruption. Adherence to treatment was assessed at each visit by pill counting.</p><p>The first patient was enrolled in March 2010, and the last patient completed the study in March 2011. The study was conducted in agreement with the principles of the Declaration of Helsinki through its recent version (59th General Assembly, Seoul 2008) and with the Good Clinical Practice guidelines (CPMP/ICH/135/1995, Directive 2001/20/EC for Europe), and the local regulations for clinical trials. The study protocol and the informed consent procedure were reviewed and approved by the Ethics Committees of the study sites. All patients provided written informed consent before any study-specific procedure was implemented.</p></sec><sec><title> Office blood pressure</title><p>Office BP was measured at all study visits with a validated semi-automatic device (Omron 705 IT; Omron Matsusaka Co. Ltd. Japan) using a cuff of appropriate size. The device provided printouts of BP values together with the time and date of the measurements. At the initial visit, BP was checked in both arms and the arm with the higher value was used for all subsequent measurements. Individuals with a between-arm BP difference more than 20&#x0200a;mmHg for systolic or more than 10&#x0200a;mmHg for diastolic were excluded from the study. Three measurements were made with the patient in the sitting position since at least 5&#x0200a;min and the average of the three values was used as the reference value for the visit. Two additional measurements were obtained immediately upon and 2&#x0200a;min after standing. For each BP value, the device also provided heart rate values in beats/minute.</p></sec><sec><title>Home blood pressure</title><p>Home BP was measured with Microlife WatchBP Home (Widnau, Switzerland), a device that has been validated according to the International Study Protocols of the European Society of Hypertension [<xref rid="R26" ref-type="bibr">26</xref>]. Patients received oral and written instructions to obtain duplicate measurements between 0600 and 0900&#x0200a;h and between 1800 and 2100&#x0200a;h on each day of the week preceding randomization to treatment and of the week prior to the last in-treatment visit. The device automatically excluded the first day measurements and provided the mean BP values of the remaining period together with the number from which the mean was calculated. As mentioned above, the home BP values obtained in the week prior to randomization were used as a criterion for patient inclusion in the study.</p></sec><sec><title>Study endpoints</title><p>The primary efficacy variable was the change from prerandomization values in office trough (24&#x0200a;&#x000b1;&#x0200a;2&#x0200a;h after dosing) sitting DBP after the 10 weeks of treatment. The main secondary efficacy variable was the corresponding change in office trough SBP. Other secondary efficacy variables were the effect of the 10 weeks of treatment on the rate of BP control (&#x0003c;140/90&#x0200a;mmHg), the responder rate (office SBP and DBP reductions, respectively, &#x0003e;20 and &#x0003e;10&#x0200a;mmHg), the home BP changes from the prerandomization week and the changes in standing office SBP and DBP.</p></sec><sec><title>Statistical analysis and sample size calculation</title><p>Enrolment of 100 patients in each group (900 total) was required to provide 90% power to detect a difference in mean change from baseline of 3&#x0200a;mmHg (considered as a clinically relevant difference) between monotherapy, combination therapy and placebo at a 0.05 two-sided significance level, assuming a common standard deviation of 6.5&#x0200a;mmHg. Considering approximately a 10% withdrawal rate recruitment of a total of 990 patients was planned.</p><p>The study population was analysed on an intention-to-treat (ITT) basis, which included all randomized individuals receiving at least one dose of the study drug who had at least one measurement of office sitting BP within 48&#x0200a;h after taking the study drug(s). The last observation carried forward (LOCF) approach was used. The analysis was performed by using an analysis of covariance (ANCOVA) with treatment and centres as main effects and baseline value as a covariate. The effect of treatment on BP was adjusted for baseline BP values. Medical history and adverse events were coded according to the Medical Dictionary for Regulatory Activities (MedDRA) coding dictionary Version 13.0. Prior and concomitant medications were coded by the WHO DRUG Q1-2010 dictionary. All analyses and summaries were conducted by using SAS System Version 9.2 (SAS Institute, Cary, North Carolina, USA).</p></sec></sec><sec sec-type="results"><title>RESULTS</title><sec><title>Study population</title><p>A total of 1638 individuals were screened. One thousand and thirty-nine individuals successfully completed the placebo run-in period and were randomly assigned to the double-blind study drug phase (Fig. <xref ref-type="fig" rid="F1">1</xref>). The primary reason for discontinuation before randomization was failure to satisfy all inclusion/exclusion criteria.</p><fig id="F1" position="float"><label>FIGURE 1</label><caption><p>Flow chart of the patients screened and found to be eligible for the study. ITT, intention-to-treat; PP, per protocol.</p></caption><graphic xlink:href="jhype-32-1700-g001"/></fig><p>As summarized in Table <xref ref-type="table" rid="T1">1</xref>, among the 1025 individuals included in the ITT population, 491 were men (47.9%) and 99.4% were white. Mean age was 53.9 years, and the percentage of individuals aged 65 years or more 13.3%; the mean BMI was 29.9&#x0200a;kg/m<sup>2</sup> and the proportion of obese individuals (BMI &#x02265; 30&#x0200a;kg/m<sup>2</sup>) about 40%. There were no statistically significant differences in demographic or other baseline characteristics between treatment groups. In the group as a whole, the mean sitting office DBP and SBP were 103.1 and 159.3&#x0200a;mmHg, respectively, again with no significant between-group differences.</p><p>Home BP measurements in the week before randomization to treatment were available in 969 patients of the ITT population. As expected, home values (148.9&#x0200a;mmHg SBP and 94.8&#x0200a;mmHg DBP, respectively) were noticeably lower than office BP values, but clearly greater than the values defined as the upper limit of home BP normality, that is 135/85&#x0200a;mmHg [<xref rid="R1" ref-type="bibr">1</xref>,<xref rid="R24" ref-type="bibr">24</xref>] (Table <xref ref-type="table" rid="T2">2</xref>).</p></sec><sec><title>Effects of treatment on office blood pressure</title><p>Table <xref ref-type="table" rid="T3">3</xref> summarizes that the 10-week treatment was associated with a significant reduction of office DBP in all groups. Compared with prerandomization values, the reductions were significantly greater with all L/E combinations (L10/E10, L10/E20, L20/E10 and L20/E20) than with placebo (<italic>P</italic>&#x0200a;&#x0003c;&#x0200a;0.001, <italic>P</italic>&#x0200a;=&#x0200a;0.003, <italic>P</italic>&#x0200a;&#x0003c;&#x0200a;0.001 and <italic>P</italic>&#x0200a;&#x0003c;&#x0200a;0.001, respectively), whereas the differences between combination treatments and monotherapies were less consistent. The largest BP-lowering effect was observed in the L20/E20 group in which DBP decreased by 15.2&#x0200a;mmHg in comparison with individuals treated with E20 alone (&#x02212;11.3&#x0200a;mmHg, <italic>P</italic>&#x0200a;=&#x0200a;0.004) and L20 alone (&#x02212;13.0&#x0200a;mmHg, <italic>P</italic>&#x0200a;=&#x0200a;0.092). Similar results were obtained for office SBP that decreased by &#x02212;19.2&#x0200a;mmHg in the L20/E20 group compared with &#x02212;13.0&#x0200a;mmHg in the L20 group (<italic>P</italic>&#x0200a;=&#x0200a;0.002) and &#x02212;15.3&#x0200a;mmHg in the E20 group (<italic>P</italic>&#x0200a;=&#x0200a;0.005). In the various treatment groups, BP reductions were similar after immediate assumption of standing position (Table <xref ref-type="table" rid="T4">4</xref>) and 2&#x0200a;min later (data not shown).</p><p>As shown in Fig. <xref ref-type="fig" rid="F2">2</xref>, the responder and normalization rates of BP values were achieved by a significantly greater percentage of individuals treated with combination therapy than with placebo and individuals treated with L20/E20 had the highest responder rate and frequency of normalization. In patients receiving the L20/E20 combination, the absolute office BP values were lower than in the placebo and monotherapy groups at all in-treatment visits (Fig. <xref ref-type="fig" rid="F3">3</xref>).</p><fig id="F2" position="float"><label>FIGURE 2</label><caption><p>Responder (upper panel) and normalization rate (lower panel) in the study groups. Responder rate was defined as a SBP and DBP reduction respectively greater than 20 and 10&#x0200a;mmHg. Normalization was defined as a BP reduction to &#x0003c;140/90&#x0200a;mmHg. E, enalapril; L, lercanidipine; P, placebo. &#x02217; and &#x00394; above histograms refer to significant difference (<italic>P</italic>&#x0200a;&#x0003c;&#x0200a;0.0001 and <italic>P</italic>&#x0200a;&#x0003c;&#x0200a;0.005, respectively) versus placebo.</p></caption><graphic xlink:href="jhype-32-1700-g002"/></fig><fig id="F3" position="float"><label>FIGURE 3</label><caption><p>Office SBP and DBP values at baseline and throughout the treatment period in differently treated groups. Explanations as in Figure <xref ref-type="fig" rid="F2">2</xref>.</p></caption><graphic xlink:href="jhype-32-1700-g003"/></fig></sec><sec><title>Effects of treatment on home blood pressure</title><p>Data on the effect of treatment on home BP were available in 854 randomized individuals (ITT population). As summarized in Table <xref ref-type="table" rid="T3">3</xref>, the placebo effect was much smaller for home than for office BP. For all active treatments, including the monotherapies, the BP-lowering effect was significantly superior to placebo. The greatest effect was exhibited by the L20/E20 treatment group in which the SBP reductions was significantly and markedly different both versus the L20 and the E20 group (&#x02212;13.2 versus &#x02212;7.7&#x0200a;mmHg, <italic>P</italic>&#x0200a;=&#x0200a;0.002, with L20 and &#x02212;9.2&#x0200a;mmHg, <italic>P</italic>&#x0200a;=&#x0200a;0.021, with E20, respectively). In patients receiving the combination therapy, the absolute BP values were lower than those observed in patients receiving placebo or monotherapies (Fig. <xref ref-type="fig" rid="F4">4</xref>).</p><fig id="F4" position="float"><label>FIGURE 4</label><caption><p>Absolute home true SBP and DBP values during treatment in differently treated groups. Explanations as in Figure <xref ref-type="fig" rid="F2">2</xref>.</p></caption><graphic xlink:href="jhype-32-1700-g004"/></fig></sec><sec><title>Safety, compliance and tolerability</title><p>Out of 1039 randomized patients, 72 (6.9%) discontinued the study, the primary reason being lack of efficacy (23 individuals, 2.2%), mostly occurring in the placebo and monotherapy groups, followed by adverse events (19 individuals, 1.8%), withdrawal of consent (17 individuals, 1.6%) and protocol violation (10 individuals, 1.0%). Two individuals (0.2%) were lost to follow-up and one discontinued for family reasons. Adherence to study medications for the overall treatment period was 99.3&#x0200a;&#x000b1;&#x0200a;3.5%, similarly for all treatment groups.</p><p>As shown in Table <xref ref-type="table" rid="T5">5</xref>, in the safety population, 240 individuals (23.2%) reported a total of 348 adverse events, 8.3% of which were considered possibly, probably or definitely related to the study drugs. Eighteen individuals (1.7%) had adverse events that led to withdrawal from the study. There was no difference among the treatment groups in the number of patients exhibiting adverse events or withdrawing from the study because of adverse events.</p><p>The most frequently occurring treatment-related adverse events were cough, tachycardia and headache. Cough occurred mainly with E20 alone (four individuals; 3.6%) or in combination with L10 (six patients, 5.1%), but was reported by only two individuals (1.7%) in the L20/E20 mg group. The percentage of patients who reported tachycardia or palpitations was highest in the L20&#x0200a;mg group (seven individuals; 6.2%); however, combination therapy with L20/E20 mg reduced this side effect to one individual only (0.9%). The percentage of patients who reported headache ranged from 0.0 to 2.6% in the various groups. Only one patient (0.9%) reported headache in the L20/E20 group. The incidence of peripheral oedema was low in all groups (0.8&#x02013;2.7%) and no case was reported in the L20/E20 group. The incidence of dizziness or hypotension was not increased by combination therapy (data not shown).</p><p>There were five not treatment-related cardiovascular and noncardiovascular events during the study. Two cases (ischemic stroke and worsening of hypertension) occurred in placebo group, one case (acute leukemia) occurred in the L10/E20 mg group and two cases (myocardial infarction and anaphylactic shock) occurred in the L20/E20 mg treatment group.</p><p>There were no clinically meaningful changes in any of the laboratory parameters, heart rate, difference between standing and sitting BP or ECGs in any of the treatment groups.</p></sec></sec><sec sec-type="discussion"><title>DISCUSSION</title><p>The population of the present study was characterized by moderate hypertension, the BP elevation clearly extending also to home BP values. In this population, the administration of L plus E at the daily dose of 20&#x0200a;mg each lowered office DBP significantly more than placebo and the combination components in monotherapy. This was associated with a similarly greater SBP reduction, a larger number (70% approximately) of responders to the drugs administration and a more common achievement of the BP value (&#x0003c;140/90&#x0200a;<monospace>mmHg</monospace>) recommended by guidelines as the target to pursue in middle age and elderly hypertensive individuals [<xref rid="R1" ref-type="bibr">1</xref>]. It can thus be concluded that the combination of 20&#x0200a;mg of E and 20&#x0200a;mg of L is an effective therapeutic measure in the large number of patients who exhibit a moderate BP increase. It should additionally be emphasized that a large number of our patients were overweight (mean BMI 29.9&#x0200a;kg/m<sup>2</sup>) or even frankly obese. This is clinically relevant because obesity is a condition frequently associated with hypertension [<xref rid="R27" ref-type="bibr">27</xref>] in which BP reduction and control are particularly difficult [<xref rid="R1" ref-type="bibr">1</xref>] and a combination of two or more drugs needs to be frequently considered.</p><p>The following additional results deserve to be discussed. First, the conclusion that the L20/E20 combination is therapeutically effective is confirmed by the home BP data provided by the study. In line with current knowledge [<xref rid="R1" ref-type="bibr">1</xref>,<xref rid="R28" ref-type="bibr">28</xref>,<xref rid="R29" ref-type="bibr">29</xref>], baseline home BP was lower than office BP, which made the overall BP-lowering effect of treatment less pronounced. Once again, however, the BP reduction obtained with the combination of 20&#x0200a;mg of either E and L was the maximal one observed, the difference being significant compared with all monotherapies, including those in whom only 20&#x0200a;mg of L or 20&#x0200a;mg of E was used.</p><p>Second, compared with placebo, all active treatments were well tolerated, and a small number of side effects was also seen for the L20/E20 combination. Indeed, the L20/E20 combination was associated with less cough and leg oedema compared with the combination components in monotherapy. Furthermore, compared with either monotherapy or the L/E combinations at lower doses, the L20/E20 combination did not increase palpitation, dizziness and heart rate and did not show any greater BP-lowering effect on standing than on sitting BP, this being the case either for BP values taken immediately and for those taken after a more prolonged exposure to orthostatic stress. Taken together, these observations imply that the combination of L and E at the highest dose has a favourable tolerability profile and that its greater BP-lowering effect does not translate into a risk of hypotensive episodes nor lead to reflex sympathetic activation.</p><p>Third, office BP was reduced throughout the treatment period with combination therapy, including the measurements made 2 weeks after randomization. As mentioned by the recent European guidelines [<xref rid="R1" ref-type="bibr">1</xref>], this may represent a further advantage for treatment because at least in hypertensive patients with a more pronounced cardiovascular risk profile, the goal BP should be achieved more promptly to ensure cardiovascular protection also against the possible occurrence of early cardiovascular morbid or fatal events [<xref rid="R3" ref-type="bibr">3</xref>]. Furthermore, recent evidence show that early achievement of BP control, such as when combination treatment is used as first step, may reduce discontinuation of the prescribed drug regimen during the chronic treatment phase [<xref rid="R26" ref-type="bibr">26</xref>,<xref rid="R30" ref-type="bibr">30</xref>]. This also translates into cardiovascular protection because treatment discontinuation is associated with a greater rate of hospitalization for cardiovascular disease [<xref rid="R31" ref-type="bibr">31</xref>&#x02013;<xref rid="R33" ref-type="bibr">33</xref>].</p><p>Two final points are worthy a mention. One, in the present study, patients exhibited an unusually large placebo effect, which is probably responsible for the fact that, except for the L/E combinations, the office BP reductions exhibited by monotherapies, although by no means quantitatively marginal, were not invariably significantly more pronounced than those seen in the placebo group. However, as known from previous studies [<xref rid="R23" ref-type="bibr">23</xref>,<xref rid="R26" ref-type="bibr">26</xref>,<xref rid="R29" ref-type="bibr">29</xref>,<xref rid="R33" ref-type="bibr">33</xref>], the placebo effect was much less pronounced with home BP measurements, which made the difference of home BP effects by active treatments and placebo more consistent. This speaks in favour of a more frequent use of home BP in antihypertensive treatment studies. Two, our study has several elements of strength, including the high number of patients recruited, the double-blind design and the high adherence to treatment in the recruited population. Perhaps the most important element of strength, however, is the high number of patients in whom BP was also measured at home over several days either before or during treatment. This allows to conclude that the effectiveness of the L/E combination applies to daily life BP.</p><p>In conclusion, in this large population of adult overweight and even frankly obese patients with moderate hypertension combination therapy with L and E proved to be more effective than placebo in reducing both office BP at trough and BP values taken at home. The greatest effect was observed with L20/E20 that lowered BP significantly more than placebo and L or E monotherapies even when home BP values were considered. Compared with monotherapies, the L20/E20 combination also showed a favourable tolerability profile, that is less cough, tachycardia/palpitations and leg oedema with no increase in dizziness or hypotension. Home BP proved to be a useful tool to evaluate the antihypertensive effect of medications because unlike office BP, it was largely devoid of the confounding effect of placebo-dependant BP fall.</p></sec><sec><title>ACKNOWLEDGEMENTS</title><sec><title>Conflicts of interest</title><p>G.M. has received personal fees as speaker/chairman or consultant from Boehringer Ing., Daiichi Sankyo, Medtronic, Menarini, Novartis, Recordati, Sanofi, Servier, Takeda in the past 3 years. X.G. received honoraria as speaker or consultant from Novartis, Daiichi-Sankyo, Bayer, Menarini in the past 3 years. A.C. has received personal fees from the main drug companies in the cardiovascular area. Y.S. has received personal fees from Recordati. H.H., D.P.-M., I.C. and P.P. have no conflicts of interest to declare.</p></sec></sec></body><back><fn-group><fn fn-type="abbr"><p>Abbreviations: ANCOVA, analysis of covariance; BP, blood pressure; ITT, intention to treat; LOCF, last observation carried forward; MedDRA, Medical Dictionary for Regulatory Activities</p></fn><fn fn-type="other"><p>Trial Registration: ClinicalTrials.gov Identifier: NCT01093807.</p></fn></fn-group><app-group><app><title>Reviewer's Summary Evaluation</title><sec><title>Reviewer 1</title><p>The effect of enalapril and lercanidipine combination at high dose has not been examined with respect to other combinations of the same compounds at lower dose, monotherapy with these compounds or placebo. In this paper the authors confirmed that enalapril and lercanidipine combination at high dose is superior than other combinations and its effects is also seen in home blood pressure. This combination has also been proved to be safe and well tolerated.</p></sec><sec><title>Reviewer 2</title><p>The study provides significant information for everyday clinical practice and has several strengths: first, the double-blind, randomized, placebo-controlled study design which renders available data of high quality; then, the large number of participants; and the use of home blood pressure monitoring, which accounts for white-coat hypertension and of equal importance attenuates the placebo effect. The inclusion of Caucasian patients alone and the under-representation of elderly patients consist the limitations of the study.</p></sec></app></app-group><ref-list><title>REFERENCES</title><ref id="R1"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mancia</surname><given-names>G</given-names></name><name><surname>Fagard</surname><given-names>R</given-names></name><name><surname>Krzysztof</surname><given-names>N</given-names></name><name><surname>Narkiewicz</surname><given-names>K</given-names></name><name><surname>Redon</surname><given-names>J</given-names></name><name><surname>Zanchetti</surname><given-names>A</given-names></name><etal/></person-group>
<article-title>2013&#x0200a;ESH/ESC Guidelines for the management of arterial hypertension</article-title>. <source><italic>J Hypertens</italic></source>
<year>2013</year>; <volume>31</volume>:<fpage>1281</fpage>&#x02013;<lpage>1357</lpage>.<pub-id pub-id-type="pmid">23817082</pub-id></mixed-citation></ref><ref id="R2"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aronow</surname><given-names>WS</given-names></name><name><surname>Fleg</surname><given-names>JL</given-names></name><name><surname>Pepine</surname><given-names>CJ</given-names></name><name><surname>Artinian</surname><given-names>NT</given-names></name><name><surname>Bakris</surname><given-names>G</given-names></name><name><surname>Brown</surname><given-names>AS</given-names></name><etal/></person-group>
<article-title>ACCF/AHA 2011 Expert Consensus Document on Hypertension in the Elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents</article-title>. <source><italic>J Am Coll Cardiol</italic></source>
<year>2011</year>; <volume>123</volume>:<fpage>2434</fpage>&#x02013;<lpage>2506</lpage>.</mixed-citation></ref><ref id="R3"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wald</surname><given-names>DS</given-names></name><name><surname>Law</surname><given-names>M</given-names></name><name><surname>Morris</surname><given-names>JK</given-names></name><name><surname>Bestwick</surname><given-names>JP</given-names></name><name><surname>Wald</surname><given-names>NJ</given-names></name></person-group>
<article-title>Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials</article-title>. <source><italic>Am J Med</italic></source>
<year>2009</year>; <volume>122</volume>:<fpage>290</fpage>&#x02013;<lpage>300</lpage>.<pub-id pub-id-type="pmid">19272490</pub-id></mixed-citation></ref><ref id="R4"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weber</surname><given-names>MA</given-names></name><name><surname>Julius</surname><given-names>S</given-names></name><name><surname>Kjeldsen</surname><given-names>SE</given-names></name><name><surname>Brunner</surname><given-names>HR</given-names></name><name><surname>Ekman</surname><given-names>S</given-names></name><name><surname>Hansson</surname><given-names>L</given-names></name><etal/></person-group>
<article-title>Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial</article-title>. <source><italic>Lancet</italic></source>
<year>2004</year>; <volume>363</volume>:<fpage>2049</fpage>&#x02013;<lpage>2051</lpage>.<pub-id pub-id-type="pmid">15207957</pub-id></mixed-citation></ref><ref id="R5"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bangalore</surname><given-names>S</given-names></name><name><surname>Kamalakkannan</surname><given-names>G</given-names></name><name><surname>Parkar</surname><given-names>S</given-names></name><name><surname>Messerli</surname><given-names>FH</given-names></name></person-group>
<article-title>Fixed-dose combinations improve medication compliance: a meta-analysis</article-title>. <source><italic>Am J Med</italic></source>
<year>2007</year>; <volume>120</volume>:<fpage>713</fpage>&#x02013;<lpage>719</lpage>.<pub-id pub-id-type="pmid">17679131</pub-id></mixed-citation></ref><ref id="R6"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Claxton</surname><given-names>AJ</given-names></name><name><surname>Cramer</surname><given-names>J</given-names></name><name><surname>Pierce</surname><given-names>C</given-names></name></person-group>
<article-title>A systematic review of the associations between dose regimens and medication compliance</article-title>. <source><italic>Clin Ther</italic></source>
<year>2001</year>; <volume>23</volume>:<fpage>1296</fpage>&#x02013;<lpage>1310</lpage>.<pub-id pub-id-type="pmid">11558866</pub-id></mixed-citation></ref><ref id="R7"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gupta</surname><given-names>AK</given-names></name><name><surname>Dahlof</surname><given-names>B</given-names></name><name><surname>Dobson</surname><given-names>J</given-names></name><name><surname>Sever</surname><given-names>PS</given-names></name><name><surname>Wedel</surname><given-names>H</given-names></name><name><surname>Poulter</surname><given-names>NR</given-names></name></person-group>
<collab>Anglo-Scandinavian Cardiac Outcomes Trial Investigators</collab><article-title>Determinants of new-onset diabetes among 19,257 hypertensive patients randomized in the Anglo-Scandinavian Cardiac Outcomes Trial: blood pressure lowering arm and the relative influence of antihypertensive medication</article-title>. <source><italic>Diabetes Care</italic></source>
<year>2008</year>; <volume>31</volume>:<fpage>982</fpage>&#x02013;<lpage>988</lpage>.<pub-id pub-id-type="pmid">18235048</pub-id></mixed-citation></ref><ref id="R8"><label>8</label><mixed-citation publication-type="book"><collab>National Institute for Health and Clinical Excellence</collab>. <source><italic>Hypertension. Clinical management of clinical hypertension in adults</italic>. NICE Clinical Guideline 127</source>. <month>8</month>
<year>2011</year>
<publisher-loc>London, UK</publisher-loc>: <publisher-name>National Clinical Guideline Centre, Royal College of Physicians</publisher-name>.</mixed-citation></ref><ref id="R9"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dahl&#x000f6;f</surname><given-names>B</given-names></name><name><surname>Sever</surname><given-names>P</given-names></name><name><surname>Poulter</surname><given-names>NR</given-names></name><name><surname>Wedel</surname><given-names>H</given-names></name><name><surname>Beevers</surname><given-names>D</given-names></name><name><surname>Caulfield</surname><given-names>M</given-names></name><etal/></person-group>
<collab>for the ASCOT investigators <italic>et al.</italic></collab><article-title>Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomized controlled trial</article-title>. <source><italic>Lancet</italic></source>
<year>2005</year>; <volume>366</volume>:<fpage>895</fpage>&#x02013;<lpage>906</lpage>.<pub-id pub-id-type="pmid">16154016</pub-id></mixed-citation></ref><ref id="R10"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jamerson</surname><given-names>K</given-names></name><name><surname>Weber</surname><given-names>MA</given-names></name><name><surname>Bakris</surname><given-names>GL</given-names></name><name><surname>Dahl&#x000f6;f</surname><given-names>B</given-names></name><name><surname>Pitt</surname><given-names>B</given-names></name><name><surname>Shi</surname><given-names>V</given-names></name><etal/></person-group>
<collab>for the ACCOMPLISH trial investigators</collab><article-title>Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients</article-title>. <source><italic>N Engl J Med</italic></source>
<year>2008</year>; <volume>359</volume>:<fpage>2417</fpage>&#x02013;<lpage>2428</lpage>.<pub-id pub-id-type="pmid">19052124</pub-id></mixed-citation></ref><ref id="R11"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lund-Johansen</surname><given-names>P</given-names></name><name><surname>Stranden</surname><given-names>E</given-names></name><name><surname>Helberg</surname><given-names>S</given-names></name><name><surname>Wessel-Aas</surname><given-names>T</given-names></name><name><surname>Risberg</surname><given-names>K</given-names></name><name><surname>Ronnevik</surname><given-names>PK</given-names></name><etal/></person-group>
<article-title>Quantification of leg oedema in postmenopausal hypertensive patients treated with lercanidipine or amlodipine</article-title>. <source><italic>J Hypertens</italic></source>
<year>2003</year>; <volume>21</volume>:<fpage>1003</fpage>&#x02013;<lpage>1010</lpage>.<pub-id pub-id-type="pmid">12714876</pub-id></mixed-citation></ref><ref id="R12"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schrier</surname><given-names>RW</given-names></name><name><surname>Estacio</surname><given-names>RO</given-names></name><name><surname>Jeffers</surname><given-names>B</given-names></name></person-group>
<article-title>Appropriate blood pressure control in NIDDM (ABCD) trial</article-title>. <source><italic>Diabetologia</italic></source>
<year>1996</year>; <volume>39</volume>:<fpage>1646</fpage>&#x02013;<lpage>1654</lpage>.<pub-id pub-id-type="pmid">8960857</pub-id></mixed-citation></ref><ref id="R13"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wing</surname><given-names>LM</given-names></name><name><surname>Reid</surname><given-names>CM</given-names></name><name><surname>Ryan</surname><given-names>P</given-names></name><etal/></person-group><collab>for the Second Australian National Blood Pressure Study Group</collab>. <article-title>A comparison of outcomes with angiotensin-converting&#x02013;enzyme inhibitors and diuretics for hypertension in the elderly</article-title>. <source><italic>N Engl J Med</italic></source>
<year>2003</year>; <volume>348</volume>:<fpage>583</fpage>&#x02013;<lpage>592</lpage>.<pub-id pub-id-type="pmid">12584366</pub-id></mixed-citation></ref><ref id="R14"><label>14</label><mixed-citation publication-type="journal"><collab>The SOLVD Investigators&#x02217;</collab><article-title>Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure</article-title>. <source><italic>N Engl J Med</italic></source>
<year>1991</year>; <volume>325</volume>:<fpage>293</fpage>&#x02013;<lpage>302</lpage>.<pub-id pub-id-type="pmid">2057034</pub-id></mixed-citation></ref><ref id="R15"><label>15</label><mixed-citation publication-type="journal"><collab>The Consensus Trial Study Group</collab><article-title>Effects of enalapril on mortality in severe congestive heart failure</article-title>. <source><italic>N Engl J Med</italic></source>
<year>1987</year>; <volume>316</volume>:<fpage>1429</fpage>&#x02013;<lpage>1435</lpage>.<pub-id pub-id-type="pmid">2883575</pub-id></mixed-citation></ref><ref id="R16"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meredith</surname><given-names>PA</given-names></name></person-group>
<article-title>Lercanidipine: a novel lipophilic dihydropyridine calcium antagonist with long duration of action and high vascular selectivity</article-title>. <source><italic>Exp Opin Invest Drugs</italic></source>
<year>1999</year>; <volume>8</volume>:<fpage>1043</fpage>&#x02013;<lpage>1062</lpage>.</mixed-citation></ref><ref id="R17"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dalla Vestra</surname><given-names>M</given-names></name><name><surname>Pozza</surname><given-names>G</given-names></name><name><surname>Mosca</surname><given-names>A</given-names></name><name><surname>Grazioli</surname><given-names>V</given-names></name><name><surname>Lapolla</surname><given-names>A</given-names></name><name><surname>Fioretto</surname><given-names>P</given-names></name><name><surname>Crepaldi</surname><given-names>G</given-names></name></person-group>
<article-title>Effect of lercanidipine compared with ramipril on albumin excretion rate in hypertensive type 2 diabetic patients with microalbuminuria: DIAL study</article-title>. <source><italic>Diab Nutr Mtab</italic></source>
<year>2004</year>; <volume>17</volume>:<fpage>259</fpage>&#x02013;<lpage>266</lpage>.</mixed-citation></ref><ref id="R18"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grassi</surname><given-names>G</given-names></name><name><surname>Quarti-Trevano</surname><given-names>F</given-names></name><name><surname>Scopelliti</surname><given-names>F</given-names></name><name><surname>Seravalle</surname><given-names>G</given-names></name><name><surname>Cuspidi</surname><given-names>C</given-names></name><name><surname>Mancia</surname><given-names>G</given-names></name></person-group>
<article-title>Effect of long term lercanidipine or hydrochlorotiazide administration on hypertension-related vascular structural changes</article-title>. <source><italic>Blood Pressure</italic></source>
<year>2006</year>; <volume>15</volume>:<fpage>268</fpage>&#x02013;<lpage>274</lpage>.<pub-id pub-id-type="pmid">17380844</pub-id></mixed-citation></ref><ref id="R19"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grassi</surname><given-names>G</given-names></name><name><surname>Seravalle</surname><given-names>G</given-names></name><name><surname>Turri</surname><given-names>C</given-names></name><name><surname>Bolla</surname><given-names>G</given-names></name><name><surname>Mancia</surname><given-names>G</given-names></name></person-group>
<article-title>Short-versus long-term effects of different dihydropyridines on sympathetic and baroreflex function in hypertension</article-title>. <source><italic>Hypertension</italic></source>
<year>2003</year>; <volume>41</volume>:<fpage>558</fpage>&#x02013;<lpage>562</lpage>.<pub-id pub-id-type="pmid">12623959</pub-id></mixed-citation></ref><ref id="R20"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mancia</surname><given-names>G</given-names></name><name><surname>Grassi</surname><given-names>G</given-names></name></person-group>
<article-title>The central sympathetic nervous system in hypertension</article-title>. <source><italic>Handb Clin Neurol</italic></source>
<year>2013</year>; <volume>117</volume>:<fpage>329</fpage>&#x02013;<lpage>335</lpage>.<pub-id pub-id-type="pmid">24095136</pub-id></mixed-citation></ref><ref id="R21"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hair</surname><given-names>PI</given-names></name><name><surname>Scott</surname><given-names>LJ</given-names></name><name><surname>Perry</surname><given-names>CM</given-names></name></person-group>
<article-title>Fixed dose-combination Lercanidipine/Enalapril</article-title>. <source><italic>Drugs</italic></source>
<year>2007</year>; <volume>67</volume>:<fpage>95</fpage>&#x02013;<lpage>106</lpage>.<pub-id pub-id-type="pmid">17209666</pub-id></mixed-citation></ref><ref id="R22"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chatzikyrkou</surname><given-names>C</given-names></name><name><surname>Haller</surname><given-names>H</given-names></name><name><surname>Menne</surname><given-names>J</given-names></name></person-group>
<article-title>Efficacy and safety of fixed-dose Lercanidipine-Enalapril for the treatment of hypertension</article-title>. <source><italic>Clin Med Ther</italic></source>
<year>2009</year>; <volume>1</volume>:<fpage>63</fpage>&#x02013;<lpage>76</lpage>.</mixed-citation></ref><ref id="R23"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parati</surname><given-names>G</given-names></name><name><surname>Stergiou</surname><given-names>GS</given-names></name><name><surname>Asmar</surname><given-names>R</given-names></name><name><surname>Bilo</surname><given-names>G</given-names></name><name><surname>de Leeuw</surname><given-names>P</given-names></name><name><surname>Imai</surname><given-names>Y</given-names></name><etal/></person-group>
<article-title>European Society of Hypertension guidelines for blood pressure monitoring at home: a summary report of the Second International Consensus Conference on Home Blood Pressure Monitoring</article-title>. <source><italic>J Hypertens</italic></source>
<year>2008</year>; <volume>26</volume>:<fpage>1505</fpage>&#x02013;<lpage>1530</lpage>.<pub-id pub-id-type="pmid">18622223</pub-id></mixed-citation></ref><ref id="R24"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mancia</surname><given-names>G</given-names></name><name><surname>Zanchetti</surname><given-names>A</given-names></name><name><surname>Agabiti-Rosei</surname><given-names>E</given-names></name><name><surname>Benemio</surname><given-names>G</given-names></name><name><surname>De Cesaris</surname><given-names>R</given-names></name><name><surname>Fogari</surname><given-names>R</given-names></name><etal/></person-group>
<article-title>Ambulatory blood pressure is superior to clinic blood pressure in predicting treatment-induced regression of left ventricular hypertrophy. SAMPLE Study Group. Study on Ambulatory Monitoring of Blood Pressure and Lisinopril Evaluation</article-title>. <source><italic>Circulation</italic></source>
<year>1997</year>; <volume>95</volume>:<fpage>1464</fpage>&#x02013;<lpage>1470</lpage>.<pub-id pub-id-type="pmid">9118514</pub-id></mixed-citation></ref><ref id="R25"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sega</surname><given-names>R</given-names></name><name><surname>Facchetti</surname><given-names>R</given-names></name><name><surname>Bombelli</surname><given-names>M</given-names></name><name><surname>Cesana</surname><given-names>G</given-names></name><name><surname>Corrao</surname><given-names>G</given-names></name><name><surname>Grassi</surname><given-names>G</given-names></name><name><surname>Mancia</surname><given-names>G</given-names></name></person-group>
<article-title>Prognostic value of ambulatory and home blood pressures compared with office blood pressure in the general population. Follow-up results from the Pressioni Arteriose Monitorate e Loro Associazioni (PAMELA) study</article-title>. <source><italic>Circulation</italic></source>
<year>2005</year>; <volume>111</volume>:<fpage>1777</fpage>&#x02013;<lpage>1783</lpage>.<pub-id pub-id-type="pmid">15809377</pub-id></mixed-citation></ref><ref id="R26"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stergiou</surname><given-names>GS</given-names></name><name><surname>Jaenecke</surname><given-names>B</given-names></name><name><surname>Giovas</surname><given-names>PP</given-names></name><name><surname>Chang</surname><given-names>A</given-names></name><name><surname>Chung-Yueh</surname><given-names>Y</given-names></name><name><surname>Tan</surname><given-names>TM</given-names></name></person-group>
<article-title>A tool for reliable self-home blood pressure monitoring designed according to the European Society of Hypertension recommendations: the Microlife WatchBP Home monitor</article-title>. <source><italic>Blood Press Monit</italic></source>
<year>2007</year>; <volume>12</volume>:<fpage>127</fpage>&#x02013;<lpage>131</lpage>.<pub-id pub-id-type="pmid">17353657</pub-id></mixed-citation></ref><ref id="R27"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bombelli</surname><given-names>M</given-names></name><name><surname>Facchetti</surname><given-names>R</given-names></name><name><surname>Fodri</surname><given-names>D</given-names></name><name><surname>Brambilla</surname><given-names>G</given-names></name><name><surname>Sega</surname><given-names>R</given-names></name><name><surname>Grassi</surname><given-names>G</given-names></name><name><surname>Mancia</surname><given-names>G</given-names></name></person-group>
<article-title>Impact of body mass index and waist circumpherence on the cardiovascular risk and all-cause death in a general population: data from the PAMELA study</article-title>. <source><italic>Nutr Metab Cardiovasc Dis</italic></source>
<year>2013</year>; <volume>23</volume>:<fpage>650</fpage>&#x02013;<lpage>656</lpage>.<pub-id pub-id-type="pmid">22633796</pub-id></mixed-citation></ref><ref id="R28"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mancia</surname><given-names>G</given-names></name><name><surname>Sega</surname><given-names>R</given-names></name><name><surname>Grassi</surname><given-names>G</given-names></name><name><surname>Cesana</surname><given-names>G</given-names></name><name><surname>Zanchetti</surname><given-names>A</given-names></name></person-group>
<article-title>Defining ambulatory and home blood pressure normality: further considerations based on data from the PAMELA study</article-title>. <source><italic>J Hypertens</italic></source>
<year>2001</year>; <volume>19</volume>:<fpage>995</fpage>&#x02013;<lpage>999</lpage>.<pub-id pub-id-type="pmid">11403368</pub-id></mixed-citation></ref><ref id="R29"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parati</surname><given-names>G</given-names></name><name><surname>Stergiou</surname><given-names>GS</given-names></name><name><surname>Asmar</surname><given-names>R</given-names></name><name><surname>Bilo</surname><given-names>G</given-names></name><name><surname>de Leeuw</surname><given-names>P</given-names></name><name><surname>Imai</surname><given-names>Y</given-names></name><etal/></person-group>
<article-title>European Society of Hypertension guidelines for blood pressure monitoring</article-title>. <source><italic>J Hum Hypertens</italic></source>
<year>2010</year>; <volume>24</volume>:<fpage>779</fpage>&#x02013;<lpage>785</lpage>.<pub-id pub-id-type="pmid">20520631</pub-id></mixed-citation></ref><ref id="R30"><label>30</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Corrao</surname><given-names>G</given-names></name><name><surname>Parodi</surname><given-names>A</given-names></name><name><surname>Zambon</surname><given-names>A</given-names></name><name><surname>Heiman</surname><given-names>F</given-names></name><name><surname>Filippi</surname><given-names>A</given-names></name><name><surname>Cricelli</surname><given-names>C</given-names></name><etal/></person-group>
<article-title>Reduced discontinuation of antihypertensive treatment by two-drug combination as first step. Evidence from daily life practice</article-title>. <source><italic>J Hypertens</italic></source>
<year>2010</year>; <volume>28</volume>:<fpage>1584</fpage>&#x02013;<lpage>1590</lpage>.<pub-id pub-id-type="pmid">20543716</pub-id></mixed-citation></ref><ref id="R31"><label>31</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Corrao</surname><given-names>G</given-names></name><name><surname>Parodi</surname><given-names>A</given-names></name><name><surname>Nicotra</surname><given-names>F</given-names></name><name><surname>Zambon</surname><given-names>A</given-names></name><name><surname>Merlino</surname><given-names>L</given-names></name><name><surname>Cesana</surname><given-names>G</given-names></name><name><surname>Mancia</surname><given-names>G</given-names></name></person-group>
<article-title>Better compliance to antihypertensive medications reduces cardiovascular risk</article-title>. <source><italic>J Hypertens</italic></source>
<year>2011</year>; <volume>29</volume>:<fpage>610</fpage>&#x02013;<lpage>618</lpage>.<pub-id pub-id-type="pmid">21157368</pub-id></mixed-citation></ref><ref id="R32"><label>32</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sokol</surname><given-names>MD</given-names></name><name><surname>McGuigan</surname><given-names>KA</given-names></name><name><surname>Verbrugge</surname><given-names>RR</given-names></name><name><surname>Epstein</surname><given-names>RS</given-names></name></person-group>
<article-title>Impact of medication adherence on hospitalization risk and healthcare cost</article-title>. <source><italic>Med Care</italic></source>
<year>2005</year>; <volume>43</volume>:<fpage>521</fpage>&#x02013;<lpage>530</lpage>.<pub-id pub-id-type="pmid">15908846</pub-id></mixed-citation></ref><ref id="R33"><label>33</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Simpson</surname><given-names>SH</given-names></name><name><surname>Eurich</surname><given-names>DT</given-names></name><name><surname>Majumdar</surname><given-names>SR</given-names></name><name><surname>Padwal</surname><given-names>RS</given-names></name><name><surname>Tsuyuki</surname><given-names>RT</given-names></name><name><surname>Varney</surname><given-names>J</given-names></name><name><surname>Johnson</surname><given-names>JA</given-names></name></person-group>
<article-title>A meta-analysis of the association between adherence to drug therapy and mortality</article-title>. <source><italic>BMJ</italic></source>
<year>2006</year>; <volume>333</volume>:<fpage>15</fpage>.<pub-id pub-id-type="pmid">16790458</pub-id></mixed-citation></ref></ref-list></back><floats-group><table-wrap id="T1" position="float"><label>TABLE 1</label><caption><p>Baseline demographic and clinical characteristics of the intention-to-treat population</p></caption><table frame="hsides" rules="groups"><thead><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Placebo <italic>N</italic>&#x02009;=&#x02009;111</td><td rowspan="1" colspan="1">E10 <italic>N</italic>&#x02009;=&#x02009;118</td><td rowspan="1" colspan="1">L10 <italic>N</italic>&#x02009;=&#x02009;116</td><td rowspan="1" colspan="1">E20 <italic>N</italic>&#x02009;=&#x02009;111</td><td rowspan="1" colspan="1">L20 <italic>N</italic>&#x02009;=&#x02009;109</td><td rowspan="1" colspan="1">L10&#x02009;+&#x02009;E10 <italic>N</italic>&#x02009;=&#x02009;116</td><td rowspan="1" colspan="1">L10&#x02009;+&#x02009;E20 <italic>N</italic>&#x02009;=&#x02009;118</td><td rowspan="1" colspan="1">L20&#x02009;+&#x02009;E10 <italic>N</italic>&#x02009;=&#x02009;110</td><td rowspan="1" colspan="1">L20&#x02009;+&#x02009;E20 <italic>N</italic>&#x02009;=&#x02009;116</td><td rowspan="1" colspan="1">Overall <italic>N</italic>&#x02009;=&#x02009;1025</td></tr></thead><tbody><tr><td rowspan="1" colspan="1">Males (%)</td><td rowspan="1" colspan="1">50.5</td><td rowspan="1" colspan="1">47.5</td><td rowspan="1" colspan="1">44.8</td><td rowspan="1" colspan="1">48.6</td><td rowspan="1" colspan="1">44.0</td><td rowspan="1" colspan="1">49.1</td><td rowspan="1" colspan="1">52.5</td><td rowspan="1" colspan="1">48.2</td><td rowspan="1" colspan="1">45.7</td><td rowspan="1" colspan="1">47.9</td></tr><tr><td rowspan="1" colspan="1">Age (years)</td><td rowspan="1" colspan="1">54.7&#x02009;&#x000b1;&#x02009;9.8</td><td rowspan="1" colspan="1">54.8&#x02009;&#x000b1;&#x02009;9.9</td><td rowspan="1" colspan="1">53.6&#x02009;&#x000b1;&#x02009;9.8</td><td rowspan="1" colspan="1">52.1&#x02009;&#x000b1;&#x02009;9.4</td><td rowspan="1" colspan="1">55.4&#x02009;&#x000b1;&#x02009;9.7</td><td rowspan="1" colspan="1">54.0&#x02009;&#x000b1;&#x02009;10.2</td><td rowspan="1" colspan="1">53.0&#x02009;&#x000b1;&#x02009;10.1</td><td rowspan="1" colspan="1">51.9&#x02009;&#x000b1;&#x02009;10.2</td><td rowspan="1" colspan="1">55.8&#x02009;&#x000b1;&#x02009;10.1</td><td rowspan="1" colspan="1">53.9&#x02009;&#x000b1;&#x02009;9.10</td></tr><tr><td rowspan="1" colspan="1">White (%)</td><td rowspan="1" colspan="1">99.1</td><td rowspan="1" colspan="1">99.2</td><td rowspan="1" colspan="1">99.1</td><td rowspan="1" colspan="1">99.1</td><td rowspan="1" colspan="1">100</td><td rowspan="1" colspan="1">100</td><td rowspan="1" colspan="1">99.2</td><td rowspan="1" colspan="1">100</td><td rowspan="1" colspan="1">99.1</td><td rowspan="1" colspan="1">99.4</td></tr><tr><td rowspan="1" colspan="1">BMI (kg/m<sup>2</sup>)</td><td rowspan="1" colspan="1">29.89&#x02009;&#x000b1;&#x02009;4.9</td><td rowspan="1" colspan="1">29.34&#x02009;&#x000b1;&#x02009;5.2</td><td rowspan="1" colspan="1">30.60&#x02009;&#x000b1;&#x02009;4.9</td><td rowspan="1" colspan="1">30.12&#x02009;&#x000b1;&#x02009;5.2</td><td rowspan="1" colspan="1">29.73&#x02009;&#x000b1;&#x02009;4.8</td><td rowspan="1" colspan="1">30.38&#x02009;&#x000b1;&#x02009;4.8</td><td rowspan="1" colspan="1">29.72&#x02009;&#x000b1;&#x02009;4.8</td><td rowspan="1" colspan="1">29.86&#x02009;&#x000b1;&#x02009;4.7</td><td rowspan="1" colspan="1">29.11&#x02009;&#x000b1;&#x02009;5.3</td><td rowspan="1" colspan="1">29.86&#x02009;&#x000b1;&#x02009;4.10</td></tr><tr><td rowspan="1" colspan="1">Office SBP (mmHg)</td><td rowspan="1" colspan="1">160.5&#x02009;&#x000b1;&#x02009;10.5</td><td rowspan="1" colspan="1">158.8&#x02009;&#x000b1;&#x02009;10.3</td><td rowspan="1" colspan="1">159.5&#x02009;&#x000b1;&#x02009;10.4</td><td rowspan="1" colspan="1">159.9&#x02009;&#x000b1;&#x02009;9.7</td><td rowspan="1" colspan="1">159.2&#x02009;&#x000b1;&#x02009;10.7</td><td rowspan="1" colspan="1">159.1&#x02009;&#x000b1;&#x02009;10.2</td><td rowspan="1" colspan="1">159.4&#x02009;&#x000b1;&#x02009;10.5</td><td rowspan="1" colspan="1">158.6&#x02009;&#x000b1;&#x02009;10.4</td><td rowspan="1" colspan="1">159.0&#x02009;&#x000b1;&#x02009;10.7</td><td rowspan="1" colspan="1">159.3&#x02009;&#x000b1;&#x02009;10.4</td></tr><tr><td rowspan="1" colspan="1">Office DBP (mmHg)</td><td rowspan="1" colspan="1">103.2&#x02009;&#x000b1;&#x02009;2.4</td><td rowspan="1" colspan="1">103.2&#x02009;&#x000b1;&#x02009;2.2</td><td rowspan="1" colspan="1">102.9&#x02009;&#x000b1;&#x02009;2.5</td><td rowspan="1" colspan="1">103.1&#x02009;&#x000b1;&#x02009;2.6</td><td rowspan="1" colspan="1">103.3&#x02009;&#x000b1;&#x02009;2.8</td><td rowspan="1" colspan="1">103.0&#x02009;&#x000b1;&#x02009;2.6</td><td rowspan="1" colspan="1">102.9&#x02009;&#x000b1;&#x02009;3.4</td><td rowspan="1" colspan="1">102.8&#x02009;&#x000b1;&#x02009;3.1</td><td rowspan="1" colspan="1">103.1&#x02009;&#x000b1;&#x02009;3.10</td><td rowspan="1" colspan="1">103.1&#x02009;&#x000b1;&#x02009;2.9</td></tr><tr><td rowspan="1" colspan="1">Office HR (b/min)</td><td rowspan="1" colspan="1">77.6&#x02009;&#x000b1;&#x02009;10.8</td><td rowspan="1" colspan="1">77.3&#x02009;&#x000b1;&#x02009;11.0</td><td rowspan="1" colspan="1">77.8&#x02009;&#x000b1;&#x02009;9.3</td><td rowspan="1" colspan="1">77.9&#x02009;&#x000b1;&#x02009;10.6</td><td rowspan="1" colspan="1">78.5&#x02009;&#x000b1;&#x02009;9.9</td><td rowspan="1" colspan="1">79.4&#x02009;&#x000b1;&#x02009;9.5</td><td rowspan="1" colspan="1">78.7&#x02009;&#x000b1;&#x02009;11.7</td><td rowspan="1" colspan="1">78.4&#x02009;&#x000b1;&#x02009;11.3</td><td rowspan="1" colspan="1">77.1&#x02009;&#x000b1;&#x02009;9.9</td><td rowspan="1" colspan="1">78.1&#x02009;&#x000b1;&#x02009;10.5</td></tr></tbody></table><table-wrap-foot><fn><p>Data are shown as % or as mean&#x02009;&#x000b1;&#x02009;standard deviation (SD). E, enalapril; HR, heart rate; ITT, intention to treat; L, lercanidipine.</p></fn></table-wrap-foot></table-wrap><table-wrap id="T2" position="float"><label>TABLE 2</label><caption><p>Baseline home DBP and SBP &#x02013; intention-to-treat population</p></caption><table frame="hsides" rules="groups"><thead><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Placebo <italic>N</italic>&#x02009;=&#x02009;105</td><td rowspan="1" colspan="1">E10&#x02009;mg <italic>N</italic>&#x02009;=&#x02009;109</td><td rowspan="1" colspan="1">L10&#x02009;mg <italic>N</italic>&#x02009;=&#x02009;110</td><td rowspan="1" colspan="1">E20&#x02009;mg <italic>N</italic>&#x02009;=&#x02009;104</td><td rowspan="1" colspan="1">L20&#x02009;mg <italic>N</italic>&#x02009;=&#x02009;103</td><td rowspan="1" colspan="1">L10&#x02009;+&#x02009;E10&#x02009;mg <italic>N</italic>&#x02009;=&#x02009;114</td><td rowspan="1" colspan="1">L10&#x02009;+&#x02009;E20&#x02009;mg <italic>N</italic>&#x02009;=&#x02009;113</td><td rowspan="1" colspan="1">L20&#x02009;+&#x02009;E10&#x02009;mg <italic>N</italic>&#x02009;=&#x02009;102</td><td rowspan="1" colspan="1">L20&#x02009;+&#x02009;E20&#x02009;mg <italic>N</italic>&#x02009;=&#x02009;109</td><td rowspan="1" colspan="1">Overall <italic>N</italic>&#x02009;=&#x02009;969</td></tr></thead><tbody><tr><td rowspan="1" colspan="1">Home SBP (mmHg)</td><td rowspan="1" colspan="1">148.0&#x02009;&#x000b1;&#x02009;12.4</td><td rowspan="1" colspan="1">147.7&#x02009;&#x000b1;&#x02009;12.3</td><td rowspan="1" colspan="1">150.8&#x02009;&#x000b1;&#x02009;12.1</td><td rowspan="1" colspan="1">147.2&#x02009;&#x000b1;&#x02009;12.3</td><td rowspan="1" colspan="1">149.8&#x02009;&#x000b1;&#x02009;12.3</td><td rowspan="1" colspan="1">150.0&#x02009;&#x000b1;&#x02009;11.5</td><td rowspan="1" colspan="1">150.1&#x02009;&#x000b1;&#x02009;11.3</td><td rowspan="1" colspan="1">148.5&#x02009;&#x000b1;&#x02009;12.0</td><td rowspan="1" colspan="1">148.0&#x02009;&#x000b1;&#x02009;11.9</td><td rowspan="1" colspan="1">148.9&#x02009;&#x000b1;&#x02009;12.0</td></tr><tr><td rowspan="1" colspan="1">Home DBP (mmHg)</td><td rowspan="1" colspan="1">93.5&#x02009;&#x000b1;&#x02009;5.6</td><td rowspan="1" colspan="1">93.6&#x02009;&#x000b1;&#x02009;6.0</td><td rowspan="1" colspan="1">95.8&#x02009;&#x000b1;&#x02009;5.8</td><td rowspan="1" colspan="1">94.9&#x02009;&#x000b1;&#x02009;7.1</td><td rowspan="1" colspan="1">94.4&#x02009;&#x000b1;&#x02009;5.6</td><td rowspan="1" colspan="1">95.5&#x02009;&#x000b1;&#x02009;5.7</td><td rowspan="1" colspan="1">95.7&#x02009;&#x000b1;&#x02009;6.3</td><td rowspan="1" colspan="1">95.6&#x02009;&#x000b1;&#x02009;6.5</td><td rowspan="1" colspan="1">94.4&#x02009;&#x000b1;&#x02009;6.1</td><td rowspan="1" colspan="1">94.8&#x02009;&#x000b1;&#x02009;6.1</td></tr><tr><td rowspan="1" colspan="1">Home HR (beats/min)</td><td rowspan="1" colspan="1">75.2&#x02009;&#x000b1;&#x02009;9.8</td><td rowspan="1" colspan="1">74.4&#x02009;&#x000b1;&#x02009;8.9</td><td rowspan="1" colspan="1">76.0&#x02009;&#x000b1;&#x02009;8.9</td><td rowspan="1" colspan="1">77.1&#x02009;&#x000b1;&#x02009;9.5</td><td rowspan="1" colspan="1">76.2&#x02009;&#x000b1;&#x02009;8.7</td><td rowspan="1" colspan="1">76.4&#x02009;&#x000b1;&#x02009;10.2</td><td rowspan="1" colspan="1">75.9&#x02009;&#x000b1;&#x02009;9.6</td><td rowspan="1" colspan="1">75.9&#x02009;&#x000b1;&#x02009;9.3</td><td rowspan="1" colspan="1">75.8&#x02009;&#x000b1;&#x02009;9.0</td><td rowspan="1" colspan="1">75.9&#x02009;&#x000b1;&#x02009;9.3</td></tr></tbody></table><table-wrap-foot><fn><p>Data are shown as % or as mean&#x02009;&#x000b1;&#x02009;standard deviation (SD). E, enalapril; HR, heart rate; ITT, intention to treat; L, lercanidipine..</p></fn></table-wrap-foot></table-wrap><table-wrap id="T3" position="float"><label>TABLE 3</label><caption><p>Adjusted office and home blood pressure changes at end of treatment in the intention-to-treat population</p></caption><table frame="hsides" rules="groups"><thead><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Placebo (<italic>N</italic>&#x02009;=&#x02009;111)</td><td rowspan="1" colspan="1">L10&#x02009;mg (<italic>N</italic>&#x02009;=&#x02009;116)</td><td rowspan="1" colspan="1">L20&#x02009;mg (<italic>N</italic>&#x02009;=&#x02009;109)</td><td rowspan="1" colspan="1">E10&#x02009;mg (<italic>N</italic>&#x02009;=&#x02009;118)</td><td rowspan="1" colspan="1">E20&#x02009;mg (<italic>N</italic>&#x02009;=&#x02009;111)</td><td rowspan="1" colspan="1">L10 + E10 (<italic>N</italic>&#x02009;=&#x02009;116)</td><td rowspan="1" colspan="1">L10&#x02009;+&#x02009;E20 (<italic>N</italic>&#x02009;=&#x02009;118)</td><td rowspan="1" colspan="1">L20&#x02009;+&#x02009;E10 (<italic>N</italic>&#x02009;=&#x02009;110)</td><td rowspan="1" colspan="1">L20&#x02009;+&#x02009;E20 (<italic>N</italic>&#x02009;=&#x02009;116)</td></tr></thead><tbody><tr><td colspan="10" rowspan="1">Office BP (<italic>N</italic>&#x02009;=&#x02009;1025)</td></tr><tr><td rowspan="1" colspan="1">SBP (mmHg)</td><td rowspan="1" colspan="1">&#x02212;9.6</td><td rowspan="1" colspan="1">&#x02212;11.0</td><td rowspan="1" colspan="1">&#x02212;13.0</td><td rowspan="1" colspan="1">&#x02212;14.7<xref ref-type="table-fn" rid="TF3-2"><sup>**</sup></xref></td><td rowspan="1" colspan="1">&#x02212;15.3<xref ref-type="table-fn" rid="TF3-2"><sup>**</sup></xref></td><td rowspan="1" colspan="1">&#x02212;15.8<xref ref-type="table-fn" rid="TF3-2"><sup>**</sup></xref></td><td rowspan="1" colspan="1">&#x02212;16.2<xref ref-type="table-fn" rid="TF3-2"><sup>**</sup></xref></td><td rowspan="1" colspan="1">&#x02212;17.1<xref ref-type="table-fn" rid="TF3-1"><sup>*</sup></xref></td><td rowspan="1" colspan="1">&#x02212;19.2<xref ref-type="table-fn" rid="TF3-1"><sup>*</sup></xref></td></tr><tr><td rowspan="1" colspan="1">DBP (mmHg)</td><td rowspan="1" colspan="1">&#x02212;8.8</td><td rowspan="1" colspan="1">&#x02212;10.4</td><td rowspan="1" colspan="1">&#x02212;13.0<xref ref-type="table-fn" rid="TF3-2"><sup>**</sup></xref></td><td rowspan="1" colspan="1">&#x02212;13.8<xref ref-type="table-fn" rid="TF3-1"><sup>*</sup></xref></td><td rowspan="1" colspan="1">&#x02212;11.3</td><td rowspan="1" colspan="1">&#x02212;14.2<xref ref-type="table-fn" rid="TF3-1"><sup>*</sup></xref></td><td rowspan="1" colspan="1">&#x02212;12.8<xref ref-type="table-fn" rid="TF3-2"><sup>**</sup></xref></td><td rowspan="1" colspan="1">&#x02212;14.0<xref ref-type="table-fn" rid="TF3-1"><sup>*</sup></xref></td><td rowspan="1" colspan="1">&#x02212;15.2<xref ref-type="table-fn" rid="TF3-1"><sup>*</sup></xref></td></tr></tbody></table><table frame="hsides" rules="groups"><thead><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Placebo (<italic>N</italic>&#x02009;=&#x02009;89)</td><td rowspan="1" colspan="1">L10&#x02009;mg (<italic>N</italic>&#x02009;=&#x02009;96)</td><td rowspan="1" colspan="1">L20&#x02009;mg (<italic>N</italic>&#x02009;=&#x02009;87)</td><td rowspan="1" colspan="1">E10&#x02009;mg (<italic>N</italic>&#x02009;=&#x02009;96)</td><td rowspan="1" colspan="1">E20&#x02009;mg (<italic>N</italic>&#x02009;=&#x02009;91)</td><td rowspan="1" colspan="1">L10&#x02009;+&#x02009;E10 (<italic>N</italic>&#x02009;=&#x02009;102)</td><td rowspan="1" colspan="1">L10&#x02009;+&#x02009;E20 (<italic>N</italic>&#x02009;=&#x02009;103)</td><td rowspan="1" colspan="1">L20&#x02009;+&#x02009;E10 (<italic>N</italic>&#x02009;=&#x02009;91)</td><td rowspan="1" colspan="1">L20&#x02009;+&#x02009;E20 (<italic>N</italic>&#x02009;=&#x02009;99)</td></tr></thead><tbody><tr><td colspan="10" rowspan="1">Home BP (<italic>N</italic>&#x02009;=&#x02009;854)</td></tr><tr><td rowspan="1" colspan="1">SBP (mmHg)</td><td rowspan="1" colspan="1">&#x02212;2.4</td><td rowspan="1" colspan="1">&#x02212;8.8<xref ref-type="table-fn" rid="TF3-1"><sup>*</sup></xref></td><td rowspan="1" colspan="1">&#x02212;7.7<xref ref-type="table-fn" rid="TF3-2"><sup>**</sup></xref></td><td rowspan="1" colspan="1">&#x02212;9.1<xref ref-type="table-fn" rid="TF3-1"><sup>*</sup></xref></td><td rowspan="1" colspan="1">&#x02212;9.2<xref ref-type="table-fn" rid="TF3-1"><sup>*</sup></xref></td><td rowspan="1" colspan="1">&#x02212;11.2<xref ref-type="table-fn" rid="TF3-1"><sup>*</sup></xref></td><td rowspan="1" colspan="1">&#x02212;10.6<xref ref-type="table-fn" rid="TF3-1"><sup>*</sup></xref></td><td rowspan="1" colspan="1">&#x02212;9.6<xref ref-type="table-fn" rid="TF3-1"><sup>*</sup></xref></td><td rowspan="1" colspan="1">&#x02212;13.2<xref ref-type="table-fn" rid="TF3-1"><sup>*</sup></xref></td></tr><tr><td rowspan="1" colspan="1">DBP (mmHg)</td><td rowspan="1" colspan="1">&#x02212;1.5</td><td rowspan="1" colspan="1">&#x02212;4.6<xref ref-type="table-fn" rid="TF3-2"><sup>**</sup></xref></td><td rowspan="1" colspan="1">&#x02212;5.5<xref ref-type="table-fn" rid="TF3-2"><sup>**</sup></xref></td><td rowspan="1" colspan="1">&#x02212;6.2<xref ref-type="table-fn" rid="TF3-1"><sup>*</sup></xref></td><td rowspan="1" colspan="1">&#x02212;5.3<xref ref-type="table-fn" rid="TF3-2"><sup>**</sup></xref></td><td rowspan="1" colspan="1">&#x02212;6.4<xref ref-type="table-fn" rid="TF3-1"><sup>*</sup></xref></td><td rowspan="1" colspan="1">&#x02212;6.5<xref ref-type="table-fn" rid="TF3-1"><sup>*</sup></xref></td><td rowspan="1" colspan="1">&#x02212;6.8<xref ref-type="table-fn" rid="TF3-1"><sup>*</sup></xref></td><td rowspan="1" colspan="1">&#x02212;7.5<xref ref-type="table-fn" rid="TF3-1"><sup>*</sup></xref></td></tr></tbody></table><table-wrap-foot><fn><p>Data refer to the differences between last on-treatment visit and baseline, adjusted for baseline values. Means&#x02009;&#x000b1;&#x02009;SD are shown. <italic>P</italic> values refer to between-group differences.</p></fn><fn id="TF3-1"><p><sup>*</sup><italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001 versus placebo.</p></fn><fn id="TF3-2"><p><sup>**</sup><italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05 versus placebo.</p></fn></table-wrap-foot></table-wrap><table-wrap id="T4" position="float"><label>TABLE 4</label><caption><p>Difference between office immediate standing and sitting blood pressure at end of treatment in the safety population (<italic>N</italic>&#x0200a;=&#x0200a;1036)</p></caption><table frame="hsides" rules="groups"><thead><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Placebo (<italic>N</italic>&#x02009;=&#x02009;113)</td><td rowspan="1" colspan="1">L10&#x02009;mg (<italic>N</italic>&#x02009;=&#x02009;117)</td><td rowspan="1" colspan="1">L20&#x02009;mg (<italic>N</italic>&#x02009;=&#x02009;113)</td><td rowspan="1" colspan="1">E10&#x02009;mg (<italic>N</italic>&#x02009;=&#x02009;119)</td><td rowspan="1" colspan="1">E20&#x02009;mg (<italic>N</italic>&#x02009;=&#x02009;111)</td><td rowspan="1" colspan="1">L10&#x02009;+&#x02009;E10 (<italic>N</italic>&#x02009;=&#x02009;117)</td><td rowspan="1" colspan="1">L10&#x02009;+&#x02009;E20 (<italic>N</italic>&#x02009;=&#x02009;118)</td><td rowspan="1" colspan="1">L20&#x02009;+&#x02009;E10 (<italic>N</italic>&#x02009;=&#x02009;112)</td><td rowspan="1" colspan="1">L20&#x02009;+&#x02009;E20 (<italic>N</italic>&#x02009;=&#x02009;116)</td></tr></thead><tbody><tr><td rowspan="1" colspan="1">SBP (mmHg)</td><td rowspan="1" colspan="1">1.0 (9.8)</td><td rowspan="1" colspan="1">&#x02212;2.9 (7.7)</td><td rowspan="1" colspan="1">&#x02212;0.5 (10.0)</td><td rowspan="1" colspan="1">&#x02212;0.5 (9.6)</td><td rowspan="1" colspan="1">0.3 (8.8)</td><td rowspan="1" colspan="1">&#x02212;0.5 (9.7)</td><td rowspan="1" colspan="1">&#x02212;2.0 (10.7)</td><td rowspan="1" colspan="1">0.5 (9.9)</td><td rowspan="1" colspan="1">&#x02212;1.1 (9.1)</td></tr><tr><td rowspan="1" colspan="1">DBP (mmHg)</td><td rowspan="1" colspan="1">2.4 (6.7)</td><td rowspan="1" colspan="1">2.8 (5.9)</td><td rowspan="1" colspan="1">3.3 (6.3)</td><td rowspan="1" colspan="1">3.5 (5.8)</td><td rowspan="1" colspan="1">2.7 (6.3)</td><td rowspan="1" colspan="1">4.1 (7.1)</td><td rowspan="1" colspan="1">3.4 (7.0)</td><td rowspan="1" colspan="1">3.5 (7.1)</td><td rowspan="1" colspan="1">2.5 (5.7)</td></tr></tbody></table></table-wrap><table-wrap id="T5" position="float"><label>TABLE 5</label><caption><p>Adverse events during the double-blind treatment period (safety population)<sup>a</sup></p></caption><table frame="hsides" rules="groups"><thead><tr><td rowspan="1" colspan="1">Adverse events</td><td rowspan="1" colspan="1">Placebo <italic>N</italic>&#x02009;=&#x02009;113</td><td rowspan="1" colspan="1">E10&#x02009;mg <italic>N</italic>&#x02009;=&#x02009;119</td><td rowspan="1" colspan="1">L10&#x02009;mg <italic>N</italic>&#x02009;=&#x02009;117</td><td rowspan="1" colspan="1">E20&#x02009;mg <italic>N</italic>&#x02009;=&#x02009;111</td><td rowspan="1" colspan="1">L20&#x02009;mg <italic>N</italic>&#x02009;=&#x02009;113</td><td rowspan="1" colspan="1">L10&#x02009;+&#x02009;E10&#x02009;mg <italic>N</italic>&#x02009;=&#x02009;117</td><td rowspan="1" colspan="1">L10&#x02009;+&#x02009;E20&#x02009;mg <italic>N</italic>&#x02009;=&#x02009;118</td><td rowspan="1" colspan="1">L20&#x02009;+&#x02009;E10&#x02009;mg <italic>N</italic>&#x02009;=&#x02009;112</td><td rowspan="1" colspan="1">L20&#x02009;+&#x02009;E20&#x02009;mg <italic>N</italic>&#x02009;=&#x02009;116</td><td rowspan="1" colspan="1">Overall <italic>N</italic>&#x02009;=&#x02009;1036</td></tr></thead><tbody><tr><td colspan="11" rowspan="1">Any TEAE</td></tr><tr><td rowspan="1" colspan="1">&#x02003;No. of events</td><td rowspan="1" colspan="1">36</td><td rowspan="1" colspan="1">34</td><td rowspan="1" colspan="1">39</td><td rowspan="1" colspan="1">43</td><td rowspan="1" colspan="1">39</td><td rowspan="1" colspan="1">30</td><td rowspan="1" colspan="1">50</td><td rowspan="1" colspan="1">35</td><td rowspan="1" colspan="1">42</td><td rowspan="1" colspan="1">348</td></tr><tr><td rowspan="1" colspan="1">&#x02003;n (%)</td><td rowspan="1" colspan="1">27 (23.9)</td><td rowspan="1" colspan="1">23 (19.3)</td><td rowspan="1" colspan="1">26 (22.2)</td><td rowspan="1" colspan="1">30 (27.0)</td><td rowspan="1" colspan="1">29 (25.7)</td><td rowspan="1" colspan="1">20 (17.1)</td><td rowspan="1" colspan="1">30 (25.4)</td><td rowspan="1" colspan="1">26 (23.2)</td><td rowspan="1" colspan="1">29 (25.7)</td><td rowspan="1" colspan="1">240 (23.2)</td></tr><tr><td colspan="11" rowspan="1">Treatment-related adverse events<xref ref-type="table-fn" rid="TF5-2"><sup>b</sup></xref></td></tr><tr><td rowspan="1" colspan="1">&#x02003;No of events</td><td rowspan="1" colspan="1">8</td><td rowspan="1" colspan="1">11</td><td rowspan="1" colspan="1">13</td><td rowspan="1" colspan="1">14</td><td rowspan="1" colspan="1">13</td><td rowspan="1" colspan="1">14</td><td rowspan="1" colspan="1">16</td><td rowspan="1" colspan="1">14</td><td rowspan="1" colspan="1">12</td><td rowspan="1" colspan="1">115</td></tr><tr><td rowspan="1" colspan="1">&#x02003;n (%)</td><td rowspan="1" colspan="1">6 (5.3)</td><td rowspan="1" colspan="1">9 (7.6)</td><td rowspan="1" colspan="1">7 (6.0)</td><td rowspan="1" colspan="1">12 (10.8)</td><td rowspan="1" colspan="1">10 (8.8)</td><td rowspan="1" colspan="1">10 (8.5)</td><td rowspan="1" colspan="1">12 (10.2)</td><td rowspan="1" colspan="1">10 (8.9)</td><td rowspan="1" colspan="1">10 (8.6)</td><td rowspan="1" colspan="1">86 (8.3)</td></tr><tr><td colspan="11" rowspan="1">Adverse events leading to withdrawal</td></tr><tr><td rowspan="1" colspan="1">&#x02003;No of events</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">4</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">21</td></tr><tr><td rowspan="1" colspan="1">&#x02003;n (%)</td><td rowspan="1" colspan="1">2 (1.8)</td><td rowspan="1" colspan="1">2 (1.7)</td><td rowspan="1" colspan="1">2 (1.7)</td><td rowspan="1" colspan="1">2 (1.8)</td><td rowspan="1" colspan="1">2 (1.8)</td><td rowspan="1" colspan="1">2 (1.7)</td><td rowspan="1" colspan="1">1 (0.8)</td><td rowspan="1" colspan="1">3 (2.7)</td><td rowspan="1" colspan="1">2 (1.7)</td><td rowspan="1" colspan="1">18 (1.7)</td></tr></tbody></table><table-wrap-foot><fn id="TF5-1"><p><sup>a</sup>Adverse events with onset or increased severity anytime after the date of first dose of double-blind study drug and up to 30 days after the last dose.</p></fn><fn id="TF5-2"><p><sup>b</sup>Considered definitely, probably or possibly related to study drug.</p></fn></table-wrap-foot></table-wrap></floats-group></article>